Pairwise
PrivateLast Round
Series C
Sep 17, 2024
Total Funding Raised
$155M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Pairwise operates in Healthcare & Life Sciences and is based in Durham, North Carolina. Its latest recorded funding round was a Series C round in September 2024.
Pairwise is an agricultural technology company that uses CRISPR gene-editing technology to develop new varieties of fruits and vegetables.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, D2C Brands
Business Model
B2B
Customer Profile
Data as a Service, Revenue Share, Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pairwise Comparables
Compare Pairwise with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ohalo | 82% | |
| Phytoform Labs | 79% | |
| Hudson River Biotechnology | 79% |
For institutional investors. Book with your work email.
Pairwise Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2024 | ||||
| Series B | Feb 3, 2021 | ||||
| Series A | Mar 20, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Pairwise Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series C, Series A, Series B |
| Temasek | Series B |
| Corteva Catalyst | Series C |
| Aliment Capital | Series C, Series B |
| Leaps by Bayer | Series C, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors grew 35% MoM, reaching 14.4K.
- Apr 22, 2026
Integrating precision-editing technology with AI-based trait discovery.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyOct 27, 2026
On Oct 29th '26, Pairwise licenses its Fulcrum(R) platform to Kaveri Seeds in India to develop improved maize, cotton, rice, pearl millet, mustard, and vegetable varieties.
- licenses_technologyOct 8, 2026
Pairwise grants Rainbow Crops BV access to its Fulcrum plant gene-editing platform under a licensing agreement, and Rainbow Crops BV integrates it into Trait Foundry for use across crop programs and collaborations with seed and breeding partners worldwide in North Carolina and Belgium on Oct 8th '26.
For institutional investors. Book with your work email.
Pairwise Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Pairwise's valuation, stock price, and market status.
Is Pairwise a public or private company?
Pairwise is a private company.
What is the current stock price of Pairwise?
Pairwise is a private company, so its shares have no public market price. Caplight tracks Pairwise's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Pairwise worth (valuation)?
Valuation information for Pairwise is not publicly available.
Can I buy Pairwise stock?
Pairwise shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Pairwise's last funding round?
Pairwise's most recent funding round was Series C on September 17, 2024.
Who are the main investors in Pairwise?
Key investors in Pairwise include Deerfield Management, Aliment Capital, Leaps by Bayer.
Will Pairwise IPO soon?
No public IPO plans have been announced for Pairwise.
How can I track Pairwise secondary market activity?
Caplight tracks bids, offers, and trades in Pairwise's shares on secondary markets.